PMID- 17000891
OWN - NLM
STAT- MEDLINE
DCOM- 20061108
LR  - 20181201
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 12
IP  - 4
DP  - 2006 Oct
TI  - Unfractionated heparin reduces the anti-platelet effects of abciximab but not 
      eptifibatide during PCI.
PG  - 458-64
AB  - In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained 
      blood samples at baseline, 10 minutes after standard weight-based abciximab 
      (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated 
      heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly 
      higher in the eptifibatide group compared with the abciximab group both before 
      (96.5% [94-100] vs. 85% [77-89.5] [adenosine diphosphate; ADP]; 89.5% [84-95] vs. 
      59% [37.5-76.5] [thrombin receptor agonist peptide; TRAP], p<0.001 for both) and 
      after UFH (95% [93-100] vs. 79% [68.8-87.5] [ADP]; 82% [77-93] vs. 51% 
      [34.5-71.3] [TRAP], p<0.001 for both). Addition of UFH significantly reduced 
      platelet inhibition in the abciximab group (85% [77-89.5] vs. 79% [68.8-87.5] 
      [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP], p<0.05 for both) but not in 
      the eptifibatide group (96.5% [94-100] vs. 95% [93-100] [ADP]; 89.5% [84-95] vs. 
      82% [77-93] [TRAP], p=ns for both). Eptifibatide achieved superior platelet 
      inhibition before but especially after UFH compared with abciximab.
FAU - Deliargyris, Efthymios N
AU  - Deliargyris EN
AD  - Wake Forest University School of Medicine, Winston-Salem, NC 27157-1045, USA.
FAU - Upadhya, Bharathi
AU  - Upadhya B
FAU - Melton, Laura G
AU  - Melton LG
FAU - Thompson, Cheryl
AU  - Thompson C
FAU - Fisher, Melrose
AU  - Fisher M
FAU - Gabriel, Don A
AU  - Gabriel DA
FAU - Dehmer, Gregory J
AU  - Dehmer GJ
FAU - Sane, David C
AU  - Sane DC
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Anticoagulants)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Peptides)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
RN  - NA8320J834 (Eptifibatide)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Anticoagulants/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Eptifibatide
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Peptides/*therapeutic use
MH  - Platelet Aggregation/drug effects
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
EDAT- 2006/09/27 09:00
MHDA- 2006/11/10 09:00
CRDT- 2006/09/27 09:00
PHST- 2006/09/27 09:00 [pubmed]
PHST- 2006/11/10 09:00 [medline]
PHST- 2006/09/27 09:00 [entrez]
AID - 12/4/458 [pii]
AID - 10.1177/1076029606293432 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2006 Oct;12(4):458-64. doi: 10.1177/1076029606293432.